The talk will also be available on zoom – details to follow

Abstract
Type 2 diabetes is a clinically and biologically heterogeneous disease driven by diverse genetic, molecular, and environmental factors. Understanding this heterogeneity is essential to move beyond one-size-fits-all approaches and toward precision prevention and treatment strategies. In this talk, I will highlight recent work from my group and collaborators that dissects the genetic and molecular subtypes of T2D. I will discuss how these insights can help us refine disease classification, improve risk prediction, and inform individualized interventions. Finally, I will outline opportunities and challenges for translating this knowledge into precision health applications aimed at optimizing diabetes prevention and care.

Bio
I lead the Genomics and Precision Medicine research group at the Novo Nordisk Foundation Center for Basic Metabolic Research at the University of Copenhagen. The group focuses on understanding the molecular and clinical heterogeneity underlying diabetes and related metabolic diseases by integrating multi-omics profiling and deep phenotype data from wearable devices. These efforts have shed light on how molecular processes and behavioral factors influence diverse clinical trajectories, responses to therapeutic interventions, and varying propensities for developing cardiovascular complications, contributing to the field of precision medicine.